Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (797)	8/25/1999 8:49:00 PM
From: sun	Respond to of 5582

If I had to guess, I would say that some people are jockeying for position, and it looks like they are mostly on the buy side. Yep, 10000 shares at ask... host.cnbc.com

To: DanZ who wrote (797)	8/25/1999 10:35:00 PM
From: Mike M	Read Replies (1) \| Respond to of 5582

In addition, the first clinical study for Zicam has been in review at the NEJM for several months. If I'm not mistaken, the average review time is approaching, so maybe we will have their disposition soon. I got the feeling from Gary that he wasn't necessarily expecting review from the first study. I wondered if the reason for the second study wasn't to clear up any ambiguity, clean up procedure (perhaps) as well as to explore other application for Zicam. I reiterate just my conjecture except for the first sentence.